Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
University of Toronto
$120,000.00
Metabolic Effects of Ketamine in Persons with Treatment-Resistant Depression: Potential Mechanism of Action and Characterizing Metabolic Biosignatures of Clinical Response
EF 2025-26
Résumé
Treatment-resistant depression (TRD), a serious and chronic mental health disorder, occurs in approximately 30% of individuals diagnosed with major depressive disorder. TRD patients are also at a higher risk of developing medical conditions such as diabetes and obesity. Many standard antidepressants can worsen these risks by increasing weight gain and insulin resistance, which in turn makes depression harder to treat. Inadequate treatment of depressive symptoms also increases the risk of cognitive impairment and suicidality. The substantial economic burden and negative impact on both health- and life-span associated with TRD emphasizes the urgency to develop safe and effective antidepressants.
Ketamine is a promising treatment for TRD as it can rapidly improve mood and reduce suicidal thoughts. However, how ketamine works, as well as its effects on metabolism (how the body processes and uses energy), are not fully understood. Research in animals suggests ketamine may influence insulin, a hormone that regulates blood sugar and supports brain function, and that these changes may be linked to improvements in mood.
The proposed study is part of a 13-week randomized controlled trial. 110 participants with TRD will be randomly assigned to receive ketamine or midazolam, an active placebo, along with cognitive behavioural therapy. Participants' mood will be assessed, and standard blood panels will be measured before and 1-month after treatment. Blood samples will be analyzed for blood sugar, insulin, cholesterol, and related markers of metabolism. Additional analyses will be performed to understand whether changes in insulin sensitivity contribute to ketamine's antidepressant effects. This will be the first human study to investigate how ketamine interacts with insulin and metabolism. The results from this study may improve our understanding of how ketamine works as well as guide the development of personalized mental health treatments.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559741
Name
Wong Sabrina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Metabolic Effects of Ketamine in Persons with Treatment-Resistant Depression: Potential Mechanism of Action and Characterizing Metabolic Biosignatures of Clinical Response
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Clinical Research; Glucose-Insulin Homeostasis; Glutamatergic Signaling; Homa-Ir; Insulin Signaling; Ketamine; Metabolism; Psychiatry; Psychopharmacology; Treatment-Resistant Depression
Abstract
Treatment-resistant depression (TRD), a serious and chronic mental health disorder, occurs in approximately 30% of individuals diagnosed with major depressive disorder. TRD patients are also at a higher risk of developing medical conditions such as diabetes and obesity. Many standard antidepressants can worsen these risks by increasing weight gain and insulin resistance, which in turn makes depression harder to treat. Inadequate treatment of depressive symptoms also increases the risk of cognitive impairment and suicidality. The substantial economic burden and negative impact on both health- and life-span associated with TRD emphasizes the urgency to develop safe and effective antidepressants.
Ketamine is a promising treatment for TRD as it can rapidly improve mood and reduce suicidal thoughts. However, how ketamine works, as well as its effects on metabolism (how the body processes and uses energy), are not fully understood. Research in animals suggests ketamine may influence insulin, a hormone that regulates blood sugar and supports brain function, and that these changes may be linked to improvements in mood.
The proposed study is part of a 13-week randomized controlled trial. 110 participants with TRD will be randomly assigned to receive ketamine or midazolam, an active placebo, along with cognitive behavioural therapy. Participants' mood will be assessed, and standard blood panels will be measured before and 1-month after treatment. Blood samples will be analyzed for blood sugar, insulin, cholesterol, and related markers of metabolism. Additional analyses will be performed to understand whether changes in insulin sensitivity contribute to ketamine's antidepressant effects. This will be the first human study to investigate how ketamine interacts with insulin and metabolism. The results from this study may improve our understanding of how ketamine works as well as guide the development of personalized mental health treatments.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wong, Sabrina
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~